Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business Becton Dickinson plans to spin off its Biosciences and ...

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies and GLP-1 drugs. See more here.

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) shares continued to trade higher as BTIG upgraded the medical device ...

After a tumultuous few years, Becton, Dickinson is undergoing course correction ... This is helped by the Embecta spinoff but also by more positive expectations of the core business performance ...

Becton Dickinson & Co., an American medical equipment company ... the spin-off of the diabetes care unit into a public company under the brand name of Embecta Corp. and she sold the surgical ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

T he SEC on Monday said that Becton, Dickinson (NYSE:BDX) agreed to pay a $175M civil penalty to settle charges that it misled investors regarding the risks associated with continued sales of and ...

In July, Embecta, a manufacturer of disposable insulin pen needles and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from ...

Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The stock has a 50 day moving average of $233.08 and a two-hundred day moving average of $233.02.